Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen
- 1.2k Downloads
The use of opioids for management of cancer-related pain has increased significantly and has been associated with a substantial rise in rates of substance abuse and diversion. There is a paucity of data not only on the prevalence of substance abuse in cancer patients, but also for issues of drug use and diversion in family caregivers. This study aimed to evaluate the frequency of risk factors for substance abuse and diversion, and abnormal urine drug screens in cancer patients receiving palliative care.
A retrospective chart review was performed for patients with cancer who were seen in the University of Virginia Palliative Care Clinic during the month of September 2012. We evaluated Opioid Risk Tool variables and total scores, insurance status, and urine drug screen results.
Of the 114 cancer patients seen in September 2012, the mean Opioid Risk Tool score was 3.79, with 43 % of patients defined as medium to high risk. Age (16–45 years old, 23 %) and a personal history of alcohol (23 %) or illicit drugs (21 %) were the most common risk factors identified. We obtained a urine drug screen on 40 % of patients, noting abnormal findings in 45.65 %.
Opioids are an effective treatment for cancer-related pain, yet substantial risk for substance abuse exits in the cancer population. Screening tools, such as the Opioid Risk Tool, should be used as part of a complete patient assessment to balance risk with appropriate relief of suffering.
KeywordsSubstance abuse Opioids Urine drug screen Palliative care
Conflict of interest
This work was not funded by any granting agency. The authors have had full control over all primary data and would agree to a review of their data by the journal, if requested.
- 1.SAMHSA (2013) Results from the 2012 National Survey on Drug Use and Health: summary of national findings: NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Center for Health Statistics and Quality, Rockville, MDGoogle Scholar
- 2.CDC (2013) Overdoses of prescription opioid pain relievers—United States, 1999-2008. Vital Signs. Atlanta GAGoogle Scholar
- 3.Governale L (2010) Outpatient prescription opioid utilization in the U.S., years 2000–2009. http://www.fda.gov/downloads/AdvisoryCommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM220950.pdf. Accessed 01 Nov 2013
- 7.Swarm RA AA, Anghelescu DL, Benedetti C, Buga S, Cleeland C, Deleon-Casasola OA, Eilers JG, Ferrell B, Green M, Janjan NA, Kamdar MM, Levy MH, Lynch M, McDowell RM, Moryl N, Nesbit SA, Paice JA, Rabow MW, Syrjala KL, Urba SG, Weinstein SM, Dwyer M, Kumar R (2013) Adult cancer pain. J Natl Compr Cancer Netw 11(8):992–1022Google Scholar
- 12.Anghelescu DL, Ehrentraut JH, Faughnan LG (2013) Opioid misuse and abuse: risk assessment and management in patients with cancer pain. J Natl Compr Cancer Netw 11(8):1023–1031Google Scholar
- 15.Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK (2009) Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 10(2):131–146PubMedCrossRefGoogle Scholar
- 16.BJA. Prescription drug monitoring program. 2013; https://www.bja.gov/ProgramDetails.aspx?Program_ID=72. Accessed 01 Nov 2013